Printer Friendly

Four Japanese Patients with Congenital Nephrogenic Diabetes Insipidus due to the AVPR2 Mutations.

1. Introduction

Nephrogenic diabetes insipidus (NDI) is a rare disease that is characterized by resistance of the distal renal tubule and collecting ducts to arginine vasopressin [1,2]. Vast majority of NDI is caused by mutations in the arginine vasopressin receptor 2 gene (AVPR2) on the X chromosome [3]. At present, more than 250 mutations have been reported [2]. Mutations in AVPR2 were classified into three types. Type-I mutants reach the cell surface but cannot bind its ligand, type-II mutant receptors have impaired intracellular transport and cannot reach the cell surface, and type-III mutants are inappropriately transcribed [4, 5].

Common symptoms in male patients are polyuria, polydipsia, fever of unknown etiology, convulsions, and vomiting, which usually develop soon after birth [6]. On the other hand, female cases have only mild symptoms [7]. Furthermore, some mutations in the AVPR2 are related to partial NDI [8, 9].

In this study, we assessed the clinical and biochemical parameters and AVPR2 status in four NDI cases of three unrelated Japanese families.

2. Subjects and Methods

2.1. Subjects. Clinical symptoms, age at diagnosis, biochemical data, and current treatment are summarized in Table 1. All four patients had polyuria and polydipsia, and results of biochemical evaluations showed high plasma antidiuretic hormone (ADH) levels. Based on these findings, NDI was suspected. The Institutional Review Board Committee of Hokkaido University approved this study (approval number 13-061). The patients' parents provided written informed consent for their children's participation in this study.

2.1.1. Case 1. A 3-month-old Japanese boy was admitted because of poor body weight gain, vomiting, and fever that had persisted for one week. He was born as a full-term infant with no complications during pregnancy.

At the time of admission, he had polyuria with a urine volume of 700-800 mL/d. Results of laboratory examinations are shown in Table 1. Findings of brain magnetic resonance imaging (MRI) were normal. Based on the polyuria and the high serum ADH level, the infant was diagnosed as having NDI, and hydrochlorothiazide was initiated. Spironolactone and potassium supplementation was added when he was 2 years old and 4 years old, respectively, and indomethacin and a protein-restricted diet were initiated when he was 6 years old. He is currently 13 years old. His height is 150 cm (-0.8 SD), and his weight is 37 kg (-0.6 SD). His urine volume is approximately 7 L/day. He has mild hydronephrosis in the right kidney. His mother is asymptomatic. The family tree of Case 1 is shown in Figure 1(a).

2.1.2. Case 2. In Case 2, poor weight gain was pointed out at the age of 4 months in this male Japanese infant. Polydipsia and polyuria were noted when he was 17 months of age. At that time, his water intake volume was approximately 3 L/d. Previously, he had experienced recurrent mild to moderate fevers of unknown etiology.

The laboratory examinations results are shown in Table 1. The water deprivation test showed elevated serum Na+, plasma osmolality, and urine osmolality (Table 2). However, the subcutaneous injection of vasopressin did not greatly increase urine osmolality. Six and a half hours after the test started, his body weight was reduced by 4.1%. Finally, his plasma ADH elevated to 110.1 pmol/L. Brain MRI findings were normal. Based on these findings, a diagnosis of partial NDI was confirmed when he was 19 months of age. Trichlormethiazide was initiated in combination with spironolactone and sodium restriction. This treatment has successfully decreased the patient's urine volume and water intake, and his body weight has caught up to near normal for his age. Now, he is 3 years old, and his height is 90.8 cm (-0.6 SD) and weight is 12.9 kg (-0.4 SD). His mother had also complained of mild polydipsia (2,000 mL/day) and polyuria from childhood, and her plasma ADH level was mildly elevated (5.90 pmol/L), but further examination has not been done. The pedigree ofthis family is shown in Figure 1(b).

2.1.3. Cases 3 and 4. Case 3 is now a 14-year-old Japanese boy. Polydipsia and polyuria were noticed at 4 years of age. He had enuresis every day from infancy. Since he had an elevated plasma ADH level (53.1 pmol/L), he was diagnosed as having NDI. The laboratory data at the time of diagnosis are shown in Table 1. He is being treated with hydrochlorothiazide, potassium supplementation, and indomethacin. Currently, his water intake is approximately 3 L/d. Case 4 is the younger sister of Case 3 and she is now 12 years old. Polydipsia and polyuria were noted when she was 4 years old after the diagnosis of NDI in Case 3. Her plasma ADH level (6.2 pmol/L) was also elevated. She was diagnosed as having NDI, and treatment with hydrochlorothiazide, potassium supplementation, and indomethacin was initiated. Their mother also complained polydipsia and polyuria since her childhood. However, her latest daily urine volume (2,000 mL/day) did not meet the diagnostic criteria for NDI. The family tree is shown in Figure 1(c).

2.2. Sequence Analysis ofAVPR2 and Study of X Chromosome Inactivation. Genomic DNA was extracted from peripheral blood leukocytes of the cases and female carriers. The AVPR2 exon was amplified by polymerase chain reaction (PCR) using the primers as reported previously [10], and PCR products were purified and sequenced directly using an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The X-inactivation patterns of female carriers were investigated by studying the polymorphic trinucleotide (CAG) repeats in the first exon of the human androgen receptor gene as reported previously [11].

3. Results

Hemizygous mutations of AVPR2 were identified in all three male patients (Figure 2). In Case 1, one base insertion caused a frame shift, generating a premature stop codon at codon 191 in exon 2 (c.299_300insA; p. K100KfsX91, designated as p.K100KfsX91). His mother was heterozygous for this mutation. Case 2 had a c.316C > T; p.R106C (designate as p.R106C) in exon 2, which was previously reported [10, 12-17]. His mother was heterozygous for this mutation. Cases 3 and 4 had a nucleotide change of G to A at position 296, resulting in the nonsense substitution (c.296G > A; p.W99X, designated as p.W99X). Their mother and Case 4 were heterozygous for the mutation. These mutations were previously reported.

The values of relative X-inactivation for the normal allele in Case 4 was 67.0%, and the values of mothers of all four patients were 65.0% (Case 1 mother), 62.0% (Case 2 mother), and 58.0% (Case 3 and 4 mother), respectively (Figure 3). Skewed X-inactivation is defined as inactivation of 75-80% of cells in the same allele [18]. Therefore, they had random X-inactivation.

4. Discussion

Currently, over 250 mutations in the AVPR2 have been described as the cause of NDI [2]. In our study, three previously reported mutations (p.K100KfsX91, p.W99X, and p.R106C) were identified [12, 17]. The mutations p.K100KfsX91 and p.W99X produced a premature stop codon, resulting in a truncated protein. Regarding p.R106C, that mutation was identified in 7.7% (5/65) of Japanese NDI patients [17] and also was identified in other Asian and ethnic populations [2, 12, 15, 16]. The p.R106C mutation occurs at CpG nucleotides, which are mutation hot spots for genetic diseases.

Although most cases of NDI are diagnosed within the first year of life, some are diagnosed later because of milder symptoms. Especially, several missense mutations have been related to mild phenotypes of NDI [14, 17, 19]. Among our cases, Case 2 with p.R106C had poor weight gain from 4 months of age. Although he did not develop severe dehydration, he had frequent episodes of mild to moderate fever until the diagnosis was made. Pediatricians should keep in mind the possibility of mild NDI during the differential diagnosis of fever with unknown etiology.

As a previous in vitro study showed that p.R106C retained a slight capacity for production of cAMP in response to AVP, p.R106C is thought to cause less severe NDI [15]. Two patients with p.R106C reported by Pasel et al. [14] had high basal urine osmolality and partial response to AVP administration. Chen et al. [15] also reported that an NDI patient with p.R106C had normal urine and plasma osmolality and plasma electrolytes, similar to our patient (Case 2).

It is thought that the development of NDI in female carriers is due to skewed X-chromosome inactivation of the normal allele. In one Japanese study, 25% of female carriers developed NDI [20]. A recent Spanish study showed a frequency of NDI in female carriers of 50% [10]. In our studies, skewed X-inactivation was not found in Case 4. This can be explained by different degrees of X-inactivation ratios in each organ as suggested previously [21, 22].

In conclusion, we report Japanese NDI patients with AVPR2 mutations (p.K100KfsX91, p.W99X, and p.R106C). There are broad phenotypic differences among the patients with the same type of mutations. In female patients, skewed X-inactivation is not always detected in peripheral blood lymphocytes. As some NDI cases do not show severe dehydration, they should be checked not only electrolyte but also their urine and serum osmolality once they suspected NDI. Low-grade fever and poor body weight gain in infant can be the clue of diagnosing mild NDI.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors' Contributions

Noriko Namatame-Ohta designed the study and wrote the initial draft of the manuscript. Shuntaro Morikawa and Toshihiro Tajima contributed to analysis and interpretation of data and assisted in the preparation of the manuscript. All other authors have contributed to data collection and interpretation and critically reviewed the manuscript. The final version of the manuscript was approved by all authors.


The authors are grateful to Dr. T. Usui (Kyoto Medical Center, Kyoto, Japan) for kindly sequencing AVPR2 in Case 2.


[1] D. Bockenhauer and D. G. Bichet, "Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus," Nature Reviews Nephrology, vol. 11, no. 10, pp. 576-588,2015.

[2] D. G. Bichet and D. Bockenhauer, "Genetic forms of nephrogenic diabetes insipidus (NDI): vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant)," Best Practice & Research Clinical Endocrinology & Metabolism, vol. 30, no. 2, pp. 263-276, 2016.

[3] M. Birnbaumer, A. Seibold, S. Gilbert et al., "Molecular cloning of the receptor for human antidiuretic hormone," Nature, vol. 357, no. 6376, pp. 333-335, 1992.

[4] T. M. Fujiwara and D. G. Bichet, "Molecular biology of hereditary diabetes insipidus," Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2836-2846, 2005.

[5] J. H. Robben, N. V. Knoers, and P. M. Deen, "Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model," American Journal of Physiology-Renal Physiology, vol. 289, no. 2, pp. F265-F272, 2005.

[6] A. F. van Lieburg, N. V. Knoers, and L. A. Monnens, "Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus," Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1958-1964, 1999.

[7] V. Neocleous, N. Skordis, C. Shammas, E. Efstathiou, N. P. Mastroyiannopoulos, and L. A. Phylactou, "Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature," Metabolism, vol. 61, no. 7, pp. 922-930, 2012.

[8] D. Bockenhauer, E. Carpentier, D. Rochdi et al., "Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus," Nephron Physiology, vol. 114, no. 1, pp. p1-p10, 2010.

[9] K. Takahashi, N. Makita, K. Manaka et al., "V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists," Journal of Biological Chemistry, vol. 287, no. 3, pp. 2099-2106, 2012.

[10] A. Garcia Castano, G. Perez de Nanclares, L. Madariaga et al., "Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study," European Journal of Pediatrics, vol. 174, no. 10, pp. 1373-1385, 2015.

[11] R. C. Allen, H. Y. Zoghbi, A. B. Moseley, H. M. Rosenblatt, and J. W. Belmont, "Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation," American Journal of Human Genetics, vol. 51, no. 6, pp. 1229-1239, 1992.

[12] D. G. Bichet, M. Birnbaumer, M. Lonergan et al., "Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus," American Journal of Human Genetics, vol. 55, no. 2, pp. 278-286, 1994.

[13] E. Albertazzi, D. Zanchetta, P. Barbier et al., "Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families," Journal of the American Society of Nephrology, vol. 11, no. 6, pp. 1033-1043, 2000.

[14] K. Pasel, A. Schulz, K. Timmermann et al., "Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families," Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 4, pp. 1703-1710, 2000.

[15] C. H. Chen, W. Y. Chen, H. L. Liu et al., "Identification of mutations in the arginine vasopressin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients," Journal of Human Genetics, vol. 47, no. 2, pp. 66-73, 2002.

[16] W. L. Boson, T. Della Manna, D. Damiani et al., "Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients," Genetic Testing, vol. 10, no. 3, pp. 157-162, 2006.

[17] M. Fujimoto, S. Okada, Y. Kawashima et al., "Clinical overview of nephrogenic diabetes insipidus based on a nationwide survey in Japan," Yonago Acta Medica, vol. 57, no. 2, pp. 85-91, 2014.

[18] J. Minks, W. P. Robinson, and C. J. Brown, "A skewed view of X chromosome inactivation," Journal of Clinical Investigation, vol. 118, no. 1, pp. 20-23, 2008.

[19] E. Spanakis, E. Milord, and C. Gragnoli, "AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance," Journal of Cellular Physiology, vol. 217, no. 3, pp. 605-617, 2008.

[20] S. Sasaki, M. Chiga, E. Kikuchi, T. Rai, and S. Uchida, "Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2," Clinical and Experimental Nephrology, vol. 17, no. 3, pp. 338-344, 2013.

[21] A. Sharp, D. Robinson, and P. Jacobs, "Age- and tissue-specific variation of X chromosome inactivation ratios in normal women," Human Genetics, vol. 107, no. 4, pp. 343-349, 2000.

[22] M. Satoh, S. Ogikubo, and A. Yoshizawa-Ogasawara, "Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor gene mutations," Endocrine Journal, vol. 55, no. 2, pp. 277-284, 2008.

Noriko Namatame-Ohta, (1,2) Shuntaro Morikawa, (1) Akie Nakamura, (1,3) Kumihiro Matsuo, (4) Masahide Nakajima, (2) Kazuhiro Tomizawa, (5) Yusuke Tanahashi, (4) and Toshihiro Tajima (1,6)

(1) Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

(2) Department of Pediatrics, Asahikawa City Hospital, 1-1-65 Kinsei-cho, Asahikawa 070-8610, Japan

(3) Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan

(4) Department of Pediatrics, Asahikawa Medical University, 2-1-1-1 Midorigaoka-higashi, Asahikawa 078-8510, Japan

(5) Department of Pediatrics, Nakashibetsu Town Hospital, West 10 South 9, Nakashibetsu 086-1110, Japan

(6) Department of Pediatrics, Jichi Children's Medical Center Tochigi, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan

Correspondence should be addressed to Noriko Namatame-Ohta;

Received 25 January 2018; Revised 23 March 2018; Accepted 16 April 2018; Published 3 July 2018

Academic Editor: Yusuke Shiozawa

Caption: Figure 1: Family trees of 4 Japanese patients with congenital nephrogenic diabetes insipidus due to the AVPR2 mutations. Family trees of (a) Case 1, (b) Case 2, and (c) Cases 3 and 4. Index cases, also indicated by arrows, are represented by filled boxes and carriers as inactivation patterns were analyzed; * polydipsia and polyuria; ** mild polydipsia; *maternal grandfather of Case 1 had tendency of polydipsia, but the detail is not clear; *as maternal grandfather of Case 2 is dependent on alcohol, and polydipsia and polyuria are not clear; ([section]) maternal grandfather of Cases 3 and 4 had a tendency of polydipsia, but the detail examination is not performed; #maternal uncle of Cases 3 and 4, who had been undergone artificial dialysis for renal failure, died at the age of forty-seven. The detail for renal failure was not clear; NA, not accessed.

Caption: Figure 2: Results of sequencing of AVPR2 mutations. Sequence chromatograms of AVPR2 in patients and their mothers. Arrows indicate mutation sites.

Caption: Figure 3: Analysis of X-chromosome inactivation. Arrows indicate the peak fluorescence intensity of the androgen CAG repeat on each X chromosome. Samples were treated with or without HpalI, and fluorescence intensities between treated and untreated samples were compared. The calculated X-inactivation percentage is shown at the bottom of each column.
Table 1: Clinical characteristics of 4 patients with
congenital nephrogenic diabetes insipidus and AVPR2

                            Case 1                 Case 2
Sex                          Male                   Male

AVPR2 mutation          c.299_300insA;      c.316C > T; p.R106C

Age *                        3 mo                  19 mo

Symptoms *               Polydipsia,            Polydipsia,
                     polyuria, poor body    polyuria, poor body
                         weight gain,        weight gain, low-
                       vomiting, fever          grade fever

Laboratory data *

Serum Na (mEq/L)             162                    139

ADH ** (pmol/L)              29.4                   12.7

Plasma osmolality            325                    280

Urine osmolality             183                    74.0

Urologic             Mild hydronephrosis    Calcification (right
complications           (right kidney)         kidney), mild
                                            hydronephrosis (left

Current treatment     HCTZ SP potassium        TCM SP sodium
                        supplement IDM          restriction

                            Case 3                 Case 4
Sex                          Male                  Female

AVPR2 mutation        c.296G > A; p.W99X     c.296G > A; p.W99X

Age *                         4y                     4y

Symptoms *           Polydipsia, polyuria   Polydipsia, polyuria

Laboratory data *

Serum Na (mEq/L)             138                    141

ADH ** (pmol/L)              53.1                   6.2

Plasma osmolality            278                    283

Urine osmolality             51.0                   175

Urologic                     None                   None

Current treatment       HCTZ potassium         HCTZ potassium
                        supplement IDM         supplement IDM

* Time of diagnosis;  ** normal range: 0.9-4.6pmol/L. ADH,
plasma antidiuretic hormone; HCTZ, hydrochlorothiazide;
SP, spironolactone; TCM, tri-chlormethiazide; IDM, indomethacin.

Table 2: Results of the water deprivation test in Case 2.

Test          Body       Body         Urine
time         weight     weight     osmolality
(hour)         (g)      loss (%)     (mOsm/L)

0             9.055                     68
1             8.980       0.8          150
2             8.905       1.6          291
3             8.855       2.2          261
4             8.795       2.8          252
5*            8.745       3.4          314
6                                      384
6.5           8.675       4.1          378

Test            Serum          Serum           ADH
time         osmolality      [Na.sup.+]      (pmol/L)
(hour)         (mOsm/L)       (mEq/L)

0                286            140            64.7
5*               292            146            91.8
6.5              295            146           110.1

Vasopressin was subcutaneously injected. ADH, plasma
antidiuretic hormone.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Case Report
Author:Namatame-Ohta, Noriko; Morikawa, Shuntaro; Nakamura, Akie; Matsuo, Kumihiro; Nakajima, Masahide; Tom
Publication:Case Reports in Pediatrics
Geographic Code:9JAPA
Date:Jan 1, 2018
Previous Article:Unsuspected Cause of Respiratory Distress: Unrecognized Esophageal Foreign Body.
Next Article:Acanthomatous Ameloblastoma of Mandible in a Paediatric Patient.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |